Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia
Φόρτωση...
Ημερομηνία
Συγγραφείς
Milionis, H. J.
Kakafika, A. I.
Tsouli, S. G.
Athyros, V. G.
Bairaktari, E. T.
Seferiadis, K. I.
Elisaf, M. S.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Am Heart J
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: Epidemiologic studies have shown that serum uric acid is a risk factor of coronary artery disease. In addition to fenofibrate, there is some evidence that atorvastatin may have a hypouricemic action, but the underlying mechanisms remain speculative. METHODS: This randomized trial was conducted to investigate the effects of atorvastatin and simvastatin on uric acid homeostasis in patients treated for primary hyperlipidemia. A total of 180 patients were enrolled; patients were randomly assigned to 40 mg/d of either atorvastatin or simvastatin. Serum lipid and metabolic parameters were measured at baseline and at 6 and 12 weeks of treatment; random urine samples were simultaneously obtained for creatinine, sodium, and uric acid determinations. RESULTS: Baseline serum uric acid levels correlated positively with the body mass index, serum insulin, creatinine, and triglyceride levels and inversely with serum HDL cholesterol levels. Both statins caused a favorable effect on lipids and a significant decrease in fibrinogen and high-sensitivity CRP levels. However, only atorvastatin reduced serum uric acid levels (from 5.6 +/- 1.7 to 4.9 +/- 1.5 mg/dL, P <.0001) by augmenting its urinary fractional excretion (from 10.4% +/- 7.9% to 12.0% +/- 7.4%, P <.01). In a multivariate logistic regression analysis, the reduction of uric acid levels was independently associated with baseline serum uric acid concentration but not to other variables, including lipid parameters (OR, 1.65; 95% CI, 1.14 to 2.40; P =.008). CONCLUSIONS: Atorvastatin (but not simvastatin) significantly lowered serum uric acid levels. This result may be in favor of a preferable choice of atorvastatin for the treatment of hyperlipidemic patients presenting with hyperuricemia.
Περιγραφή
Λέξεις-κλειδιά
Female, Heptanoic Acids/*pharmacology/therapeutic use, Homeostasis/drug effects, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology/therapeutic use, Hyperlipidemias/blood/*drug therapy/metabolism, Hypolipidemic Agents/pharmacology/therapeutic use, Lipids/blood, Logistic Models, Male, Middle Aged, Pyrroles/*pharmacology/therapeutic use, Simvastatin/*pharmacology/therapeutic use, Uric Acid/*blood/urine
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/15459594
http://ac.els-cdn.com/S0002870304001930/1-s2.0-S0002870304001930-main.pdf?_tid=1655067b424c589f38d4488b003c0410&acdnat=1333534263_7b77309ea7546fdcffd4abb52b9d2a7b
http://ac.els-cdn.com/S0002870304001930/1-s2.0-S0002870304001930-main.pdf?_tid=1655067b424c589f38d4488b003c0410&acdnat=1333534263_7b77309ea7546fdcffd4abb52b9d2a7b
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής